Nelson Wang, MD; Abdul Salam, PhD; Ruth Webster, PhD; et al.
free access
has audio
JAMA Cardiol. 2020;5(11):1219-1226. doi:10.1001/jamacardio.2020.2739
This secondary analysis of a randomized clinical trial investigates the association of antihypertensive triple drug fixed-dose combination therapy with therapeutic inertia and prescribing patterns compared with usual care.
-
Podcast:
Low-Dose Triple Combination Therapy and Therapeutic Inertia and Prescribing Patterns in Hypertension
-
Editorial
Choosing an Initial Therapeutic Approach for Hypertension鈥擳ime for a Fixed-Dose Combination First?
Ann Marie Navar, MD, PhD; Thomas J. Wang, MD
JAMA Cardiol
-
Podcast:
Low-Dose Triple Combination Therapy and Therapeutic Inertia and Prescribing Patterns in Hypertension
Syed Shahyan Bakhtiyar, MBBS; Elizabeth L. Godfrey, BS; Shayan Ahmed, MBBS, MPH; et al.
free access
has audio
JAMA Cardiol. 2020;5(11):1227-1235. doi:10.1001/jamacardio.2020.2795
This cross-sectional study assesses survival outcomes among patients on the heart transplant waiting list during the past 3 decades and examines the association of ventricular assist devices and the 2006 United Network for Organ Sharing allocation policy with survival.
-
Podcast:
Survival on the Heart Transplant Waiting List
Thomas A. Gaziano, MD, MSc; Gregg C. Fonarow, MD; Eric J. Velazquez, MD; et al.
free access
JAMA Cardiol. 2020;5(11):1236-1244. doi:10.1001/jamacardio.2020.2822
This economic evaluation assesses the cost-effectiveness of inpatient initiation of sacubitril-valsartan vs enalapril compared with no initiation or posthospitalization initiation of sacubitril-valsartan in patients who have heart failure with reduced ejection fraction.
-
Editor's Note
The Use of Sacubitril/Valsartan for Hospitalized Heart Failure鈥擶hy Do We Care About Cost and Value?
Clyde W. Yancy, MD, MSc; Adrian F. Hernandez, MD, MHS; Robert O. Bonow, MD, MS
JAMA Cardiol
Brian Whisenant, MD; Samir R. Kapadia, MD; Mackram F. Eleid, MD; et al.
free access
JAMA Cardiol. 2020;5(11):1245-1252. doi:10.1001/jamacardio.2020.2974
This cohort study assesses contemporary outcomes of mitral valve-in-valve replacement with the SAPIEN 3 transcatheter heart valve.
Nicholas A. Marston, MD, MPH; Marc P. Bonaca, MD, MPH; Petr Jarolim, MD, PhD; et al.
free access
JAMA Cardiol. 2020;5(11):1255-1262. doi:10.1001/jamacardio.2020.2981
This cohort substudy investigates whether the addition of high-sensitivity troponin level to guideline-derived atherosclerotic cardiovascular disease risk can improve risk classification and downstream treatment recommendations.
Valentina O. Puntmann, MD, PhD; M. Ludovica Carerj, MD; Imke Wieters, MD; et al.
open access
JAMA Cardiol. 2020;5(11):1265-1273. doi:10.1001/jamacardio.2020.3557
This cohort study evaluates the presence of myocardial injury in unselected patients recently recovered from coronavirus disease 2019 (COVID-19).